studies

552A AASLD ABSTRACTS HEPATOLOGY, October, 2015
dishes, in contrast to none pre-treated LPCs. Conclusion. Taken
together, these results strongly suggest that IL-17 could contribute
to HCC development, especially by leading LPC to acquire
cancer stem cell-like properties. Therefore, IL-17 neutralization
or IL-17 signaling pathway disruption in LPCs may contribute to
CSC niche eradication in HCC treatment.
Disclosures:
Jean-Michel Pawlotsky - Consulting: Abbvie, Achillion, Bristol-Myers Squibb, Gilead,
Janssen, Merck; Speaking and Teaching: Bristol-Myers Squibb, Gilead,
Merck, Janssen
The following authors have nothing to disclose: Imène Gasmi, Adrien Guillot,
Nabila Hamdaoui, Arthur Brouillet, Julien Calderaro, Benoit Rousseau, Fouad
Lafdil
694
Growth Factor Mobilized CD34+ Bone Marrow Stem
Cells (BMSCs) Rescue the Loss of Regenerative Microenvironment
in Decompensated liver Cirrhosis
Sheetalnath B. Rooge 1 , Lovkesh Anand 2 , Dhananjay Kumar 1 ,
Smriti Shubham 1 , Rakhi Maiwall 2 , Chhagan Bihari 3 , Anupam
Kumar 1 , Shiv K. Sarin 2 ; 1 Department of Research, Institute of
Liver and Biliary Sciences (ILBS), New Delhi, India; 2 Department
of Hepatology, Institute of Liver and Biliary Sciences (ILBS), New
Delhi, India; 3 Department of Pathology, Institute of Liver and Biliary
Sciences (ILBS), New Delhi, India
Background: Therapeutic effect of growth factor mobilized
CD34+ BMSCs in management of chronic Liver Disease (CLD)
has been shown by several investigators including our group
(Gastroenterology 2012, 2015). However the underlying
mechanisms operating in the hepatic tissue are not clearly
understood. Aim: To study the cellular & molecular mechanisms
of growth factor activities on liver regeneration in CLD
patients. Patients & Method: Fourty-one Patients with cirrhosis
were administered growth factors [G-CSF at 5mcg/kg at days
1,2,3,4,5 & then every 3rd day till day 60, Erythropoietin
at 500 I.U/Kg s/c twice a week for 2 months & tranjugular
liver biopsy & hepatic vein samples were obtained before
& after the therapy. Regenerative response was studied by
immunohistochemistry (IHC) using CK19 for hepatic progenitor
cells, Ki67 for hepatocyte replication. Associated cellular
microenvironment was analyzed by IHC by using cell type
specific markers i.e. myofibroblasts (α-SMA), BMSCs (CD34),
tissue macrophage (CD68) & M2 macrophages (CD163).
Further, to study the change in secretary microenvironment a
panel of cytokines, chemokines & growth factors were analyzed
in hepatic vein plasma using Millipore Milliplex Map
Kit & compared between responders (